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Background: Optimal management of patients with classical trigeminal neuralgia (TN) requires specific treatment
programs and close collaboration between medical, radiological and surgical specialties. Organization of such
treatment programs has never been described before. With this paper we aim to describe the implementation and
feasibility of an accelerated cross-speciality management program, to describe the collaboration between the involved
specialties and to report the patient flow during the first 2 years after implementation. Finally, we aim to stimulate
discussions about optimal management of TN.
Methods: Based on collaboration between neurologists, neuroradiologists and neurosurgeons a standardized
program for TN was implemented in May 2012 at the Danish Headache Center (DHC). First out-patient visit and
subsequent 3.0 Tesla MRI scan was booked in an accelerated manner. The MRI scan was performed according to
a special TN protocol developed for this program. Patients initially referred to neurosurgery were re-directed to
DHC for pre-surgical evaluation of diagnosis and optimization of medical treatment. Follow-up was 2 years with
fixed visits where medical treatment and indication for neurosurgery was continuously evaluated. Scientific data
was collected in a structured and prospective manner.
Results: From May 2012 to April 2014, 130 patients entered the accelerated program. Waiting time for the first
out-patient visit was 42 days. Ninety-four percent of the patients had a MRI performed according to the special
protocol after a mean of 37 days. Within 2 years follow-up 35 % of the patients were referred to neurosurgery after a
median time of 65 days. Five scientific papers describing demographics, clinical characteristics and neuroanatomical
abnormalities were published.
Conclusion: The described cross-speciality management program proved to be feasible and to have acceptable
waiting times for referral and highly specialized work-up of TN patients in a public tertiary referral centre for headache
and facial pain. Early high quality MRI ensured correct diagnosis and that the neurosurgeons had a standardized basis
before decision-making on impending surgery. The program ensured that referral of the subgroup of patients in
need for surgery was standardized, ensured continuous evaluation of the need for adjustments in pharmacological
management and formed the basis for scientific research.
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Classical trigeminal neuralgia (TN) is characterized by
brief, very severe, shock-like pain paroxysms usually uni-
laterally in the 2nd and/or 3rd trigeminal branch [1, 2].
The diagnosis and management of TN traditionally lies
in the hands of neurologists, anaesthesiologists, dentists,
neurosurgeons and neuroradiologists. A close collabor-
ation between these specialists would be ideal but is often
complex and difficult to implement. Due to the relatively
low lifetime prevalence of the disease of 0.3 % [3], the clin-
ical experience even for pain specialists, is limited. Man-
agement of TN should be based on scientific evidence and
clinical experience and be handled by experts as TN can
be difficult to diagnose and treatment can cause trouble-
some side effects and complications [4–8]. Therefore,
centralization leading to a high number of referrals is
important because it allows sufficient experience for
the treating clinicians [9]. Furthermore, a collaborative
referral strategy between the involved specialties is im-
portant to ensure standardized and efficient management
of the disease. To our knowledge, there are no previous
papers describing the organization of TN patient care and
how to implement a cross-speciality management pro-
gram for TN.
The aims of TN management are: (a) to ensure that
diagnosis is correct; (b) to exclude secondary causes by
appropriate history, neuroimaging and clinical and labora-
tory examinations; (c) to optimize medical treatment and
educate the patient in how to titrate medication up and
down according to the level of pain and side-effects; (d) to
decide whether, when and what type of neurosurgical
intervention that should be performed and finally; (e) to
prospectively collect scientific data about TN. To meet
these requirements, a coherent accelerated management
program for TN was implemented in May 2012 in a col-
laborative effort between three departments.
The aims of this paper are to describe the implementa-
tion and practical organization of this cross-speciality
management program with particular emphasis on the
collaboration between the specialties. Furthermore, we
aim to report the flow of patients during the first 2 years
after implementation of this practice. It is the overall
aim to create scientific awareness of TN management
and to inspire discussions about how TN ideally should
be handled in clinical practice.
Methods
The Danish Headache Center (DHC) is a public tertiary
medical referral centre for headache and facial pain. It
was established in 2001 and has since then received and
treated headache and TN patients from all over Denmark.
With increasing clinical experience and collaboration
with the Danish patient organization in TN “Trigeminus
Foreningen” we recognized that the work-up, diagnosis,medical treatment and referral to and follow up after
neurosurgery were highly variable and inconsistent both
at our centre and nationally. This led to meetings with
consultants from the Departments of Neuroradiology
and Neurosurgery, to discuss how work-up, treatment
and research could be optimized.
Structure of the accelerated treatment program
In May 2012 we implemented an accelerated work-up
and treatment program with a seamless patient path based
on a formal collaboration between the neurologically staffed
DHC (TH, SM, RHJ and LB), the Department of Radiology
(FW) and the Department of Neurosurgery (PR). Patients
were referred to DHC directly from general practitioners,
private neurologists or hospital departments. Patients
referred directly to the Department of Neurosurgery
were re-directed to DHC for MRI and pre-surgical evalu-
ation of diagnosis and medical treatment. The accelerated
work-up and treatment program is outlined in Fig. 1.
Due to lack of resources the general waiting time for
headache patients at DHC is up to 2 years. We therefore
find it necessary to prioritize patients with the most se-
vere or potential serious disorders such as TN, cluster
headache and idiopathic intracranial hypertension. The aim
was to see TN patients within 2–6 weeks after referral. As
to patients re-directed from the Department of Neurosur-
gery the aim was to book their first out-patient visit within
2–4 weeks. At the first out-patient visit the previous diag-
nosis and treatment were re-evaluated. The diagnosis was
initially based on the 2nd edition of the International
Classification of Headache Disorders (ICHD-2) [10], but
from June 2013 the diagnosis was based on the beta-version
of ICHD-3 [1]. Categorical and quantitative variables
were systematically collected in a semi-structured inter-
view, designed for this TN management program. The
interviewing clinician paid special attention to onset,
periodicity, localization, character, intensity and frequency
of pain and accompanying autonomic symptoms, to en-
sure correct diagnose. The patients were systematically
questioned about previous treatments related to TN in-
cluding; efficacy, duration, dosage and side effects of
medical treatment and previous neurosurgical interven-
tion. Scientific data was collected in a structured and
prospective manner. It was confirmed by the Danish
National Committee on Health Research Ethics ID number
H-1-2012-093 that the project did not need ethical ap-
proval or patient’s informed consent.
The clinical examination included full routine clinical
and neurological examination with special emphasis on
trigeminal sensory function. A cotton swap and pin was
used to examine touch and pinprick respectively, in all
three branches of the trigeminal nerve. Examination of
the intraoral sensory function of the mucosa of the cheeks
and on either side of the tongue was tested with a cotton
Fig. 1 Algorithm of the accelerated work-up and treatment program. The three specialties involved in the work-up, diagnosis and treatment
collaborate closely to secure a seamless patient path. TN: classical trigeminal neuralgia, DHC: Danish Headache Center, ICHD-3 beta: beta-version
of the 3rd International Classification of Headache Disorders
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tematically with a cotton swap. The majority of patients
had already been thoroughly examined by a dentist to
exclude odontogenic causes of pain. If not, patients were re-
ferred to their own dentist if this was considered relevant.
At the first out-patient visit, thorough oral and written
information about the disease, its causes and potential
medical and neurosurgical treatments were given. The
written information was developed in collaboration be-
tween the involved neurologists and neurosurgeons. After
the first visit patients were referred to a 3.0 Tesla MRI
scan performed according to a special protocol [11, 12],
designed to visualize the trigeminal nerve and its relations,
and to identify symptomatic trigeminal neuralgia. The
neuroradiologist described the MRI blinded to pain side.
The aim was to perform the MRI within 4 weeks after the
first out-patient visit.Medical treatment and the cross-speciality team
Medical treatment was adjusted at fixed out-patient visits
at 3 and 9 months after the first visit and thereafter ac-
cording to need. Phone consultations with trained head-
ache nurses at DHC could also be booked and the nurses
could book additional consultations with the doctors, if
needed. Patients were followed for at least 2 years in order
to optimize medical treatment and the need for referral to
neurosurgical treatment was continuously evaluated. At
each follow-up visit at DHC the treating neurologist
performed a semi-structured interview, recording whether
the patient was in remission, type and dose of medical
treatment and its effects and side effects.
Patients were treated according to the international
guidelines developed by the American Academy of Neur-
ology and the European Federation of Neurological Societies
[13]. First choice medical treatment was carbamazepine
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imum tolerated dose. Second choice was oxcarbazepine
titrated in the same manner. If there was a response to
carbamazepine or oxcarbazepine but unacceptable side
effects at high doses, we used add-on treatments where
first choice was gabapentin, then pregabalin and lamotri-
gine in sufficient and tolerable dosages. Only one combin-
ation treatment was tried and if the side effects to even
low doses of carbamazepine or oxcarbazepine were un-
acceptable, we used gabapentin, pregabalin or lamotrigine,
as monotherapy or in combination.
After pain freedom or insignificant pain for at least
1 month we encouraged patients to taper medication by
one or half a tablet every seven to 14 days. In case of se-
vere pain exacerbation that could not be controlled with
oral treatments patients were admitted to in-patient treat-
ment to optimize medical treatment. In severe cases patients
were treated with intravenous loading of fosphenytoin.
We defined failed medical treatment as lack of efficacy
or intolerable side effects to carbamazepine, oxcarbazepine
and to a combination of the best of these drugs and gaba-
pentin, pregabalin or lamotrigine. In such case neurosurgi-
cal treatment was suggested to the patient. Oral and
written information about the efficacy and potential com-
plications for each type of surgical intervention was given
by the treating neurologist. Preferably, a close relative or a
friend should accompany the patient during oral informa-
tion. We focused the consultation on the patient’s current
quality of life, pain intensity and on the medical side effects
with respect to physical, social and psychological functions.
This was weighed against the expected chance of a suc-
cessful outcome of surgery and the potential surgical
complications. Indication for surgery and its efficacy and
potential complications were also discussed with the pa-
tient by the neurosurgeon, who was responsible for the
final decision about surgery. Microvascular decompression
was first choice surgical treatment when a neurovascular
contact was demonstrated on the MRI and there were no
contraindications to open neurosurgery. Second choice
was percutaneous balloon compression. If neither micro-
vascular decompression nor balloon compression did have
effect percutaneous glycerol blockade was offered as third
choice. Patients that were treated with microvascular de-
compression were routinely seen in the outpatient clinic at
the Department of Neurosurgery 3 months after surgery.
All neurosurgical treated patients were routinely seen in
the outpatient clinic at DHC at standardized visits 3, 6, 12
and 24 months postoperatively to evaluate efficacy,
complications, patient satisfaction and the need for med-
ical treatment after surgery.
Evaluation of the patient flow
To evaluate the feasibility of the implemented manage-
ment program and the patient flow the first 2 years wedescribe the referral pattern of TN patients from May
2012 to April 2014. We evaluated the waiting time of re-
ferral and work-up and whether and when the patient
was referred to neurosurgery within this period. Patients
who had been treated at DHC before May 2012 were ex-
cluded as were patients with communication barriers and
patients who for some reason did not enter the acceler-
ated program.Statistical analyses
Continuous data are summarized by descriptive statistics.
Categorical variables are presented with frequency distri-
butions (N, %) and 95 % confidence intervals. Chi square
and Fisher’s exact tests were used as appropriate to assess
associations of categorical variables. P-values are reported
as two-tailed with a significance level of 5 %. SAS 9.3 (SAS
Institute, Inc., Cary, NC, USA) were used for all analyses.Results
Two hundred and seven patients with suspected TN were
referred to DHC from May 2012 to April 2014 (Fig. 2).
Sixty-six (31 %) patients were referred from general practi-
tioners, 41 (19 %) from private neurologists and 68 (32 %)
from other hospital departments. Forty (19 %) patients
were re-directed from the Department of Neurosurgery.
In 66 (31 %) patients the referral diagnosis of TN was not
correct. Referral diagnosis was most frequently changed to
persistent idiopathic facial pain (33 (50 %)), symptomatic
trigeminal neuralgia (12 (18 %)) and cluster headache
(6 (9 %)) (Fig. 2). Eight patients were referred to DHC
with other diagnosis than TN and were diagnosed with
TN at the first out-patient visit. Thus, 149 patients were
diagnosed with TN in the inclusion period. Hereof 130
patients entered the accelerated treatment program.
Nineteen (13 %) patients were not included in the ac-
celerated program. Seven patients were pain free at their
first visit and did not want further controls, four patients
did not enter the program for unknown reasons, three
patients preferred treatment closer to home, three had
tumors not related to TN, one patient had Alzheimer’s
and one died of cause unrelated to TN, before further
follow-up.
Significantly more women (86 (66 %)) than men (44
(34 %)) entered the accelerated treatment program, p <
0.001. Mean age of disease onset was 55 (95 % CI 52.6 -
57.4) years and the mean age at referral was 62 (95 % CI
59.4–64.6) years. Mean duration of the disease was 7
(95 % CI 5.3–8.2) years. The median waiting time for the
first out-patient visit was 42 days, range 6 to 154 days.
For subsequent 3.0 Tesla MRI the median waiting time
was 37 days, range 0 to 168 days. Data from 21 patients
were not included in the analysis as 13 patients had their
protocol MRI done before their first out-patient visit
Fig. 2 Flowchart of included patients. Inclusion period lasted from May 2012 to April 2014. TN: Classical trigeminal neuralgia, DHC: Danish Headache
Center. *Diagnosis changed to: persistent idiopathic facial pain (PIFP) (N = 33), symptomatic trigeminal neuralgia (N = 12), cluster headache (N = 6),
headache not elsewhere classified (N = 5), tension type headache (N = 3), migraine (N = 3), medication-overuse headache (N = 2), occipital
neuralgia (N = 1), painful trigeminal neuropathy attributed to other disorder (N = 1). **Diagnosis changed from: PIFP (N = 4), tension type headache
(N = 2), cluster headache (N = 1), headache not elsewhere classified (N = 1). ***Reasons for missing inclusion: pain free and did not want further controls
(N = 7), unknown (N = 4), patient preferred treatment closer to home (N = 3), tumor not related to TN (N = 3), communication barrier ((Alzheimer’s)
N = 1), death not related to TN (N = 1). **** Type of surgery: microvascular decompression (MVD) (N = 29), balloon compression (N = 10), both
balloon compression and MVD within 12 months (N = 2), glycerol injection (N = 1), failed balloon compression due to bradycardia (N = 1). *****Did
not undergo surgery due to: the neurosurgeon decided not to operate (N = 2), surgery was cancelled as the patient was pain free (N = 1)
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the special protocol.
Referral to neurosurgery
Of the 130 TN patients who entered the accelerated
treatment program 46 (35 %) were referred to neurosur-
gery after a median time of 65 days (range 0–588 days).
Twenty-five of the 130 TN patients, who entered the
program, were initially re-directed to DHC from the
department of neurosurgery. Twelve (48 %) of these re-
directed patients were referred back to neurosurgery
after a median of 20 days (range 0–92 days) after their
first out-patient visit. A total of 46 patients were referredto evaluation for surgery, 43 underwent surgery, hereof 29
(67 %) had microvascular decompression, 10 (24 %) bal-
loon compression, two had both microvascular decom-
pression and balloon compression, one glycerol blockade,
while one failed balloon compression due to bradycardia.
The three patients that were not operated continued med-
ical treatment and follow-up at DHC.
Medical treatment and follow-up
Eighty-four patients were not referred to neurosurgery
but continued medical treatment at DHC. Hereof, 56
(67 %) patients were taking medications at their third
medical follow up. Of the 28 patients who were not taking
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in remission. The remaining 6 patients had tolerable pain
and preferred to be without medicine. Data was missing
in three patients. The median time of the third medical
follow up was 308 days after the first outpatient visit.
Thirty-five (63 %) of the patients who were taking medi-
cine at their third medical follow up were receiving
monotherapy with either carbamazepine or oxcarbazepine.
Twelve (21 %) were taking gabapentin, pregabalin or a
tricyclic antidepressant as monotherapy. Nine (16 %)
were taking combination treatments. Six (7 %) patients
were admitted acutely at the for in-patients treatment
due to pain exacerbations. None were treated with intra-
venous fosphenytoin.
Collection of scientific data
Scientific data were collected on all the included patients.
This data collection has made it possible to describe
demographics of the included patients in this paper as
well as the clinical characteristics and neuroanatomical
abnormalities of our patient population, which so-far
has resulted in five publications [11, 12, 14–16].
Discussion
The most important experiences from the implementa-
tion of the described cross-speciality TN management
program were that it proved to be feasible to standardize
the referral pathway and work-up, that the program
ensured acceptable waiting times, and that early high-
quality MRI ensured correct diagnosis and a standardized
basis before decision-making on impending surgery. More-
over, the referral of the subgroup of patients in need for
surgery was not unacceptably prolonged and the man-
agement program ensured continuous evaluation of
pharmacological and surgical management, and provides
the basis for scientific research. The described program
has also facilitated centralization of expertise in TN and
a close collaboration between the involved neurological,
neurosurgical and neuroradiological departments ensures
a higher volume of TN patients per clinician. The import-
ance of this is supported by Kalkanis et al. who docu-
mented that the morbidity rate was lower at specialized
high-volume surgical centres [17].
Reduction of waiting time
Because TN is one of the most painful diseases known
to mankind a short waiting time for out-patient work-up
and treatment is important. Early diagnosis will save some
TN patients from unnecessary dental treatments [16] and
years of suboptimal medical treatment. Median waiting
time for the first out-patient visit was 42 and 37 days for
subsequent MRI, which we consider acceptable in a public
health care system. It is our clinical experience that the
waiting time for first out-patient visit has been reducedsignificantly since implementation. Likewise it is our clin-
ical experience that the waiting time has been lower and
the quality of the MRI description higher after implemen-
tation of the program. The specific TN protocol for the
3.0 Tesla MRI scans not only enables the neurologist to
ensure correct diagnosis and rule out symptomatic causes
of pain, but also gives the neurosurgeon a standardized
basis for decision-making before impending neurosurgery.
Based on feedback from TN patients and patient’s orga-
nizations the reduction of waiting time has led to higher
patient satisfaction.
Prior to the implementation of the program we did not
register waiting time or patient satisfaction specifically for
TN patients, so we cannot provide scientific documenta-
tion for improvement of these parameters after imple-
mentation of the program. However, with the described
structured and accelerated manner of referral we dem-
onstrate a relatively short and acceptable waiting time
for diagnosis and imaging.
When are the medical intractable patients referred to
neurosurgery?
The median time from the first out-patient visit at DHC
to referral to neurosurgery was approximately 2 months
for all patients but only 20 days for patients who were
initially referred to neurosurgery and then re-directed to
DHC for pre-surgical evaluation. This delay must be
considered acceptable given that the patients on average
had suffered from TN for 7 years and considering that
even among those initially referred for surgery and then
re-directed to DHC for pre-surgical evaluation, half could
be sufficiently controlled be medical management. Thus,
the accelerated work-up and treatment program ensures
that patients with medically intractable pain are quickly
referred to neurosurgery. In addition, for the patients who
were initially referred to neurosurgery, who could be
controlled on medical treatment, the re-direction to DHC
reduced their waiting time for optimization of medical
treatment and ensured that these patients did not undergo
neurosurgery with its potential complications.
With the limited scientific evidence regarding efficacy
of medical treatment [18–20], there is no single answer
as to how many medications should be tried out before
a TN patient is deemed medically refractory and surgery
should be considered. Moreover, there is a lack of well-
designed neurosurgical studies using independent evalu-
ators of the efficacy and complications of microvascular
decompression [21, 22], which makes the decision process
even more challenging.
Mono- or combination therapy
The international guidelines [13] on TN treatment rec-
ommend carbamazepine and oxcarbazepine as first line
treatment based on clinical studies [5, 6, 23, 24]. Other
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same extent but some smaller studies showed promising
results using pregabalin [25], lamotrigine [26], baclofen
[27] and gabapentin [28]. In the international guidelines
it is stated that “if any of these sodium-channel blockers
(carbamazepine or oxcarbazepine, edt.) are ineffective,
referral for a surgical consultation would be a reasonable
next step” [13]. However, the guidelines also state that
“considering the relatively narrow mechanism of action
of the available drugs (carbamazepine, edt.), combination
treatments might be useful” [13].
Based on our clinical experience we agree with the inter-
national treatment guidelines although we find that refer-
ral for neurosurgery after failed monotherapy may be too
hasty and we in general try out a combination treatment
before referral to surgery. Unfortunately, the scientific
support for combination treatment is sparse and there
are no published studies directly comparing monother-
apy with polytherapy [29]. We suggest that follow up
on medical treatment should remain in the hands of ex-
perts until the condition is stable and the patient is fa-
miliar with the program of titrating up and tapering of
medication according to the level of pain and side ef-
fects. We suggest that 2 years of follow up is appropriate,
but this depends on the resources of the clinic and the
health care system.Collection of scientific data and methodological
considerations
The described structured management program has made
it possible to prospectively collect scientific data, which
so far has resulted in five publications, while several other
manuscripts are in preparation. This is an important ad-
vantage of the systematic approach to patient management,
since there is a huge need for scientific research in TN
both with respect to controlled drug trials as well as to de-
termine the optimal time for referral to surgery, i.e., which
and how many drugs should be tried before surgery should
be considered. To meet this need for evidence we are
currently prospectively following a large representative
population of TN patients at DHC to document efficacy,
side effects, complications and patient satisfaction after
medical and surgical treatment in an open label design.
The outlined management program is not based on scien-
tific evidence but on clinical experience which is a limita-
tion. Although the presented data are not evidence based,
we consider it important to describe our management
program due to the lack of prior reports on how to
structure TN management in clinical practice. We sug-
gest this description of the management as a starting
point from which to make adjustments, start discussions
and collect scientific evidence on treatment efficacy and
patient satisfaction.Conclusions
According to initial feedback from patients and clinicians,
the newly implemented accelerated cross-speciality man-
agement program represents an improvement of our TN
management by means of an acceptable waiting time, fast
diagnosis and high-quality neuroimaging by specialists
and standardized treatment and information to patients.
We demonstrate that a formal collaboration across med-
ical, diagnostic and surgical specialties is feasible at a re-
gional and national level. Furthermore, we show that
enrolment in a structured management program like this
does not hold patients with medically intractable pain
back for unacceptably long time before referral to neuro-
surgery and that the medical treatment is properly tested
before impending neurosurgery. In our opinion, this is
crucial to secure a high quality of TN management. We
encourage other centres to publish their experiences with
structured management programs in TN and to collect
scientific evidence for the efficacy and side effects of
medical and surgical treatment.
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